公开(公告)号：EP2447253A1

公开(公告)日：2012-05-02

申请号：EP10791138.0

申请日：2010-05-27

申请人： Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China

发明人： LI, Song ,  XU, Xiaoqian ,  ZHAO, Guoming ,  WANG, Lili ,  GUAN, Hua ,  XIAO, Junhai ,  ZHONG, Wu ,  ZHENG, Zhibing ,  XIE, Yunde ,  LI, Xingzhou ,  WANG,Xiaokui ,  ZHOU, Xinbo ,  LIU, Hongying

IPC分类号： C07D239/20 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  A61K31/505 ,  A61K31/506 ,  A61P31/12

CPC分类号： C07D239/20 ,  A61K31/4025 ,  A61K31/4453 ,  A61K31/505 ,  A61K31/506 ,  A61K45/06 ,  C07D211/14 ,  C07D239/28 ,  C07D239/557 ,  C07D401/06 ,  C07D403/06 ,  A61K2300/00

摘要： Disclosed are dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof. Specifically, the compounds of shown in general formula (I), or their isomers, pharmaceutically acceptable salts or hydrates are provided, wherein each variable has the meaning as defined in the description. Also provided are a process for preparing the compounds of the general formula (I), the use of the compounds, an isomer thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof as a medicament, in particular as a medicament for the treatment and/or prevention of Hepatitis B.

摘要翻译： 本发明公开了二氢嘧啶化合物及制备方法，药物组合物及其用途。 具体地，提供在（I）中所示的通式中，或它们的异构体，药学上可接受的盐或水合物的化合物，worin每个变量具有如说明书中所定义的含义。 这样提供了用于制备通式（I），使用的化合物的的化合物的方法，以它们的异构体，药学上可接受的盐或其作为药物用于治疗水合物作为药物，特别是和/ 或预防乙肝

公开(公告)号：EP2186795A1

公开(公告)日：2010-05-19

申请号：EP08800493.2

申请日：2008-08-13

申请人： Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China

发明人： LI, Song ,  ZHONG, Wu ,  ZHENG, Zhibing ,  ZHOU, Xinbo ,  XIAO, Junhai ,  XIE, Yunde ,  WANG, Lili ,  LI, Xingzhou ,  ZHAO, Guoming ,  WANG, Xiaokui ,  LIU, Hongying

IPC分类号： C07C279/16 ,  C07C279/02 ,  A61K31/155 ,  A61P31/12 ,  A61P11/00

CPC分类号： C07C279/16 ,  C07B2200/07 ,  C07C277/06 ,  C07C277/08 ,  C07C2601/08

摘要： The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.

公开(公告)号：EP2184277A1

公开(公告)日：2010-05-12

申请号：EP08783534.4

申请日：2008-07-18

申请人： Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China

发明人： LI, Song ,  YANG, Yanbo ,  XIAO, Junhai ,  ZHONG, Wu ,  ZHENG, Zhibing ,  LI, Xingzhou ,  XIE, Yunde ,  WANG, Lili ,  LIU, Hongying

IPC分类号： C07D239/24 ,  A61K31/505 ,  A61P3/00 ,  A61P3/06 ,  A61P3/08 ,  A61P3/04 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/04 ,  A61P5/48

CPC分类号： C07D239/26

摘要： The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Various substituents in the formula (I) are as defined in the specification. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I), the preparation method of compound of formula (I), and the use of the compound for the preparation of a medicament for treating and/or preventing human peroxisome proliferators activated receptor δ (hPPARδ) -associated diseases and risk factors.

摘要翻译： 本发明涉及式（I）化合物或其药学上可接受的盐或溶剂合物。 式（I）中的各种取代基如说明书中所定义。 本发明还涉及包含式（I）化合物，式（I）化合物的制备方法和该化合物在制备用于治疗和/或预防人类过氧化物酶体增殖物的药物中的用途的药物组合物 活化受体（hPPAR））相关疾病和危险因素。

公开(公告)号：EP2005945A2

公开(公告)日：2008-12-24

申请号：EP06775361.6

申请日：2006-08-11

申请人： Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China

发明人： LI, Song ,  ZHONG, Wu ,  XIAO, Junhai ,  XIE, Yunde ,  LI, Xingzhou ,  CUI, Hao ,  ZHENG, Zhibing

IPC分类号： A61K9/14 ,  A61K31/16 ,  A61P31/12

CPC分类号： A61K31/215 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/141 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652

摘要： The present invention relates to an oseltamivir phosphate granule and preparation method thereof. The said granule comprises 1.97-19.8 wt.% oseltamivir phosphate, 75.0-97.5 wt.% diluent, 0.1-5.0 wt.% binder, optionally 1.0-5.0 wt.% edible flavouring essence, sweetener and/or edible pigment. It is prepared by using 30-55v/v% aqueous ethanol solution as moistening agent. The granules prepared by the formulation and method according to the present invention have good uniformity and stability and are water-soluble. The administration dosage of the granules can be conveniently selected based on the age and body weight of patients. The oseltamivir phosphate granule is suitable for administering to old people, children and flu gravis patients and those patients that swallow inconveniently or difficultly. The preparation of the granule is simple and low in production cost.

摘要翻译： 本发明涉及磷酸奥司他韦颗粒及其制备方法。 所述颗粒包含1.97-19.8重量％的磷酸奥司他韦，75.0-97.5重量％的稀释剂，0.1-5.0重量％的粘合剂，任选的1.0-5.0重量％的可食用调味香精，甜味剂和/或可食用颜料。 通过使用30-55v / v％乙醇水溶液作为润湿剂制备。 通过本发明的制剂和方法制备的颗粒具有良好的均匀性和稳定性，并且是水溶性的。 可以根据患者的年龄和体重方便地选择颗粒的给药剂量。 奥司他韦磷酸盐颗粒适用于老年人，儿童和流感重症患者以及吞咽困难或困难的患者。 颗粒的制备简单，生产成本低。